Global Preclinical Assets Production, Demand and Key Producers, 2022-2028

December 2022 | 123 pages | ID: G872FAB19658EN
GlobalInfoResearch

Abstracts

This report studies the global Preclinical Assets demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Preclinical Assets, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2021 as the base year. This report explores demand trends and competition, as well as details the characteristics of Preclinical Assets that contribute to its increasing demand across many markets.

The global Preclinical Assets market size is expected to reach $ million by 2028, rising at a market growth of % CAGR during the forecast period (2022-2028).

Highlights and key features of the study

Global Preclinical Assets total market, 2017-2028, (USD Million)

Global Preclinical Assets total market by region & country, CAGR, 2017-2028, (USD Million)

U.S. VS China: Preclinical Assets total market, key domestic companies and share, (USD Million)

Global Preclinical Assets revenue by player and market share 2017-2022, (USD Million)

Global Preclinical Assets total market by Type, CAGR, 2017-2028, (USD Million)

Global Preclinical Assets total market by Application, CAGR, 2017-2028, (USD Million)

This reports profiles major players in the global Preclinical Assets market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Eurofins Scientific, Viroclinics Xplore, SGS, Intertek Group, AmplifyBio, IQVIA, ICON plc, Medpace and Pharmatest Services, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Preclinical Assets market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2017-2028 by year with 2021 as the base year, 2022 as the estimate year, and 2028 as the forecast year.

Global Preclinical Assets Market, By Region:

• United States
• China
• Europe
• Japan
• South Korea
• ASEAN
• India
• Rest of World

Global Preclinical Assets Market, Segmentation by Type

• Bioanalysis and DMPK Studies
• Toxicology Testing
• Compound Management
• Safety Pharmacology
• Others

Global Preclinical Assets Market, Segmentation by Application

• Biopharmaceutical Companies
• Government Institutes
• Research institutes
• Others

Companies Profiled:

• Eurofins Scientific
• Viroclinics Xplore
• SGS
• Intertek Group
• AmplifyBio
• IQVIA
• ICON plc
• Medpace
• Pharmatest Services
• PPD
• Crown Bioscience
• Comparative Biosciences
• TCG Lifesciences
• Domainex
• Absorption Systems

Key Questions Answered

1. How big is the global Preclinical Assets market?

2. What is the demand of the global Preclinical Assets market?

3. What is the year over year growth of the global Preclinical Assets market?

4. What is the total value of the global Preclinical Assets market?

5. Who are the major players in the global Preclinical Assets market?

6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

1.1 Preclinical Assets Introduction
1.2 World Preclinical Assets Market Size & Forecast (2017 & 2021 & 2028)
1.3 World Preclinical Assets Total Market by Region
  1.3.1 World Preclinical Assets Market Size by Region (2017-2028)
  1.3.2 United States Preclinical Assets Market Size (2017-2028)
  1.3.3 China Preclinical Assets Market Size (2017-2028)
  1.3.4 Europe Preclinical Assets Market Size (2017-2028)
  1.3.5 Japan Preclinical Assets Market Size (2017-2028)
  1.3.6 South Korea Preclinical Assets Market Size (2017-2028)
  1.3.7 ASEAN Preclinical Assets Market Size (2017-2028)
  1.3.8 India Preclinical Assets Market Size (2017-2028)
1.4 Market Drivers, Restraints and Trends
  1.4.1 Preclinical Assets Market Drivers
  1.4.2 Factors Affecting Demand
  1.4.3 Preclinical Assets Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
  1.5.1 Influence of COVID-19
  1.5.2 Influence of Russia-Ukraine War

2 WORLD PRECLINICAL ASSETS COMPANIES COMPETITIVE ANALYSIS

2.1 World Preclinical Assets Revenue by Player (2017-2022)
2.2 Industry Rank and Concentration Rate (CR)
  2.2.1 Global Preclinical Assets Industry Rank of Major Players
  2.2.2 Global Concentration Ratios (CR4) for Preclinical Assets in 2021
  2.2.3 Global Concentration Ratios (CR8) for Preclinical Assets in 2021
2.3 Preclinical Assets Company Evaluation Quadrant
2.4 Preclinical Assets Market: Overall Company Footprint Analysis
  2.4.1 Preclinical Assets Market: Region Footprint
  2.4.2 Preclinical Assets Market: Company Product Type Footprint
  2.4.3 Preclinical Assets Market: Company Product Application Footprint
2.5 Competitive Environment
  2.5.1 Historical Structure of the Industry
  2.5.2 Barriers of Market Entry
  2.5.3 Factors of Competition
2.6 Mergers, Acquisitions Activity

3 UNITED STATES VS CHINA VS REST OF THE WORLD

3.1 United States VS China: Preclinical Assets Market Comparison
  3.1.1 United States VS China: Preclinical Assets Market Size Comparison (2017 & 2021 & 2028)
  3.1.2 United States VS China: Preclinical Assets Market Size Market Share Comparison (2017 & 2021 & 2028)
3.2 United States Preclinical Assets Major Players and Market Share, 2017-2022
  3.2.1 Major Players of Preclinical Assets in United States, Headquarters (States, Country)
  3.2.2 United States Preclinical Assets Revenue by Domestic Player, (2017-2022)
3.3 China Preclinical Assets Major Players and Market Share, 2017-2022
  3.3.1 Major Players of Preclinical Assets in China, Headquarters (Province, Country)
  3.3.2 China Preclinical Assets Revenue by Domestic Player, (2017-2022)
3.4 Rest of World Preclinical Assets Major Players and Market Share, 2017-2022
  3.4.1 Major Players of Preclinical Assets in Rest of World, Headquarters (State, Country)
  3.4.2 Rest of World Preclinical Assets Revenue by Domestic Player, (2017-2022)

4 MARKET ANALYSIS BY TYPE

4.1 World Preclinical Assets Market Size Overview by Type: 2017 VS 2021 VS 2028
4.2 Segment Introduction by Type
  4.2.1 Bioanalysis and DMPK Studies
  4.2.2 Toxicology Testing
  4.2.3 Compound Management
  4.2.4 Safety Pharmacology
  4.2.5 Others
4.3 Market Segment by Type
  4.3.1 World Preclinical Assets Market Size by Type (2017-2022)
  4.3.2 World Preclinical Assets Market Size by Type (2023-2028)
  4.3.3 World Preclinical Assets Market Size Market Share by Type (2017-2028)

5 MARKET ANALYSIS BY APPLICATION

5.1 World Preclinical Assets Market Size Overview by Application: 2017 VS 2021 VS 2028
5.2 Segment Introduction by Application
  5.2.1 Biopharmaceutical Companies
  5.2.2 Government Institutes
  5.2.3 Research institutes
  5.2.4 Others
  5.2.5 Others
5.3 Market Segment by Application
  5.3.1 World Preclinical Assets Market Size by Application (2017-2022)
  5.3.2 World Preclinical Assets Market Size by Application (2023-2028)
  5.3.3 World Preclinical Assets Market Size by Application (2017-2028)

6 COMPANY PROFILES

6.1 Eurofins Scientific
  6.1.1 Eurofins Scientific Details
  6.1.2 Eurofins Scientific Major Business
  6.1.3 Eurofins Scientific Preclinical Assets Product and Services
  6.1.4 Eurofins Scientific Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022)
  6.1.5 Eurofins Scientific Recent Developments/Updates
  6.1.6 Eurofins Scientific Competitive Strengths & Weaknesses
6.2 Viroclinics Xplore
  6.2.1 Viroclinics Xplore Details
  6.2.2 Viroclinics Xplore Major Business
  6.2.3 Viroclinics Xplore Preclinical Assets Product and Services
  6.2.4 Viroclinics Xplore Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022)
  6.2.5 Viroclinics Xplore Recent Developments/Updates
  6.2.6 Viroclinics Xplore Competitive Strengths & Weaknesses
6.3 SGS
  6.3.1 SGS Details
  6.3.2 SGS Major Business
  6.3.3 SGS Preclinical Assets Product and Services
  6.3.4 SGS Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022)
  6.3.5 SGS Recent Developments/Updates
  6.3.6 SGS Competitive Strengths & Weaknesses
6.4 Intertek Group
  6.4.1 Intertek Group Details
  6.4.2 Intertek Group Major Business
  6.4.3 Intertek Group Preclinical Assets Product and Services
  6.4.4 Intertek Group Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022)
  6.4.5 Intertek Group Recent Developments/Updates
  6.4.6 Intertek Group Competitive Strengths & Weaknesses
6.5 AmplifyBio
  6.5.1 AmplifyBio Details
  6.5.2 AmplifyBio Major Business
  6.5.3 AmplifyBio Preclinical Assets Product and Services
  6.5.4 AmplifyBio Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022)
  6.5.5 AmplifyBio Recent Developments/Updates
  6.5.6 AmplifyBio Competitive Strengths & Weaknesses
6.6 IQVIA
  6.6.1 IQVIA Details
  6.6.2 IQVIA Major Business
  6.6.3 IQVIA Preclinical Assets Product and Services
  6.6.4 IQVIA Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022)
  6.6.5 IQVIA Recent Developments/Updates
  6.6.6 IQVIA Competitive Strengths & Weaknesses
6.7 ICON plc
  6.7.1 ICON plc Details
  6.7.2 ICON plc Major Business
  6.7.3 ICON plc Preclinical Assets Product and Services
  6.7.4 ICON plc Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022)
  6.7.5 ICON plc Recent Developments/Updates
  6.7.6 ICON plc Competitive Strengths & Weaknesses
6.8 Medpace
  6.8.1 Medpace Details
  6.8.2 Medpace Major Business
  6.8.3 Medpace Preclinical Assets Product and Services
  6.8.4 Medpace Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022)
  6.8.5 Medpace Recent Developments/Updates
  6.8.6 Medpace Competitive Strengths & Weaknesses
6.9 Pharmatest Services
  6.9.1 Pharmatest Services Details
  6.9.2 Pharmatest Services Major Business
  6.9.3 Pharmatest Services Preclinical Assets Product and Services
  6.9.4 Pharmatest Services Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022)
  6.9.5 Pharmatest Services Recent Developments/Updates
  6.9.6 Pharmatest Services Competitive Strengths & Weaknesses
6.10 PPD
  6.10.1 PPD Details
  6.10.2 PPD Major Business
  6.10.3 PPD Preclinical Assets Product and Services
  6.10.4 PPD Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022)
  6.10.5 PPD Recent Developments/Updates
  6.10.6 PPD Competitive Strengths & Weaknesses
6.11 Crown Bioscience
  6.11.1 Crown Bioscience Details
  6.11.2 Crown Bioscience Major Business
  6.11.3 Crown Bioscience Preclinical Assets Product and Services
  6.11.4 Crown Bioscience Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022)
  6.11.5 Crown Bioscience Recent Developments/Updates
  6.11.6 Crown Bioscience Competitive Strengths & Weaknesses
6.12 Comparative Biosciences
  6.12.1 Comparative Biosciences Details
  6.12.2 Comparative Biosciences Major Business
  6.12.3 Comparative Biosciences Preclinical Assets Product and Services
  6.12.4 Comparative Biosciences Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022)
  6.12.5 Comparative Biosciences Recent Developments/Updates
  6.12.6 Comparative Biosciences Competitive Strengths & Weaknesses
6.13 TCG Lifesciences
  6.13.1 TCG Lifesciences Details
  6.13.2 TCG Lifesciences Major Business
  6.13.3 TCG Lifesciences Preclinical Assets Product and Services
  6.13.4 TCG Lifesciences Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022)
  6.13.5 TCG Lifesciences Recent Developments/Updates
  6.13.6 TCG Lifesciences Competitive Strengths & Weaknesses
6.14 Domainex
  6.14.1 Domainex Details
  6.14.2 Domainex Major Business
  6.14.3 Domainex Preclinical Assets Product and Services
  6.14.4 Domainex Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022)
  6.14.5 Domainex Recent Developments/Updates
  6.14.6 Domainex Competitive Strengths & Weaknesses
6.15 Absorption Systems
  6.15.1 Absorption Systems Details
  6.15.2 Absorption Systems Major Business
  6.15.3 Absorption Systems Preclinical Assets Product and Services
  6.15.4 Absorption Systems Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022)
  6.15.5 Absorption Systems Recent Developments/Updates
  6.15.6 Absorption Systems Competitive Strengths & Weaknesses

7 RAW MATERIAL AND INDUSTRY CHAIN

7.1 Raw Material of Preclinical Assets and Key Manufacturers
7.2 Preclinical Assets Manufacturing Costs
7.3 Preclinical Assets Production Process
7.4 Preclinical Assets Industrial Chain

8 DISTRIBUTION CHANNEL ANALYSIS

8.1 Distribution Channel Breakdown for Preclinical Assets Shipments (%): 2017-2028
  8.1.1 Direct Channel
  8.1.2 Indirect Channel
8.2 Preclinical Assets Typical Distributors
8.3 Preclinical Assets Typical Customers

9 RESEARCH FINDINGS AND CONCLUSION

10 APPENDIX

10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World Preclinical Assets Market Size by Region (2017, 2022 and 2028) & (USD Million)
Table 2. World Preclinical Assets Market Size by Region (2017-2022) & (USD Million)
Table 3. World Preclinical Assets Market Size by Region (2023-2028) & (USD Million)
Table 4. World Preclinical Assets Market Size Market Share by Region (2017-2022)
Table 5. World Preclinical Assets Market Size Market Share by Region (2023-2028)
Table 6. Major Market Trends
Table 7. World Preclinical Assets Revenue by Player (2017-2022) & (USD Million)
Table 8. Revenue Market Share of Key Preclinical Assets Players in 2021
Table 9. World Preclinical Assets Industry Rank of Major Player, Based on Revenue in 2021
Table 10. Global Preclinical Assets Company Evaluation Quadrant
Table 11. Head Office of Key Preclinical Assets Player
Table 12. Preclinical Assets Market: Company Product Type Footprint
Table 13. Preclinical Assets Market: Company Product Application Footprint
Table 14. Preclinical Assets Mergers & Acquisitions Activity
Table 15. United States VS China Preclinical Assets Market Size Comparison, (2017 & 2021 & 2028) & (USD Million)
Table 16. Major Player of Preclinical Assets in United States, Headquarters (States, Country)
Table 17. United States Preclinical Assets Revenue by Domestic Player, (2017-2022) & (USD Million)
Table 18. United States Preclinical Assets Revenue Market Share by Domestic Player, (2017-2022)
Table 19. Major Player of Preclinical Assets in China, Company Headquarters (Province, Country)
Table 20. China Preclinical Assets Revenue by Domestic Player, (2017-2022) & (USD Million)
Table 21. China Preclinical Assets Revenue Market Share by Domestic Player, (2017-2022)
Table 22. Major Player of Preclinical Assets in Rest of World, Company Headquarters (State, Country)
Table 23. Rest of World Preclinical Assets Revenue by Domestic Player, (2017-2022) & (USD Million)
Table 24. Rest of World Preclinical Assets Revenue Market Share by Domestic Player, (2017-2022)
Table 25. World Preclinical Assets Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 26. World Preclinical Assets Revenue by Type (2017-2022) & (USD Million)
Table 27. World Preclinical Assets Revenue by Type (2023-2028) & (USD Million)
Table 28. World Preclinical Assets Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 29. World Preclinical Assets Revenue by Application (2017-2022) & (USD Million)
Table 30. World Preclinical Assets Revenue by Application (2023-2028) & (USD Million)
Table 31. Eurofins Scientific Basic Information, Area Served and Competitors
Table 32. Eurofins Scientific Major Business
Table 33. Eurofins Scientific Preclinical Assets Product and Services
Table 34. Eurofins Scientific Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 35. Eurofins Scientific Recent Developments/Updates
Table 36. Eurofins Scientific Competitive Strengths & Weaknesses
Table 37. Viroclinics Xplore Basic Information, Area Served and Competitors
Table 38. Viroclinics Xplore Major Business
Table 39. Viroclinics Xplore Preclinical Assets Product and Services
Table 40. Viroclinics Xplore Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 41. Viroclinics Xplore Recent Developments/Updates
Table 42. Viroclinics Xplore Competitive Strengths & Weaknesses
Table 43. SGS Basic Information, Area Served and Competitors
Table 44. SGS Major Business
Table 45. SGS Preclinical Assets Product and Services
Table 46. SGS Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 47. SGS Recent Developments/Updates
Table 48. SGS Competitive Strengths & Weaknesses
Table 49. Intertek Group Basic Information, Area Served and Competitors
Table 50. Intertek Group Major Business
Table 51. Intertek Group Preclinical Assets Product and Services
Table 52. Intertek Group Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 53. Intertek Group Recent Developments/Updates
Table 54. Intertek Group Competitive Strengths & Weaknesses
Table 55. AmplifyBio Basic Information, Area Served and Competitors
Table 56. AmplifyBio Major Business
Table 57. AmplifyBio Preclinical Assets Product and Services
Table 58. AmplifyBio Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 59. AmplifyBio Recent Developments/Updates
Table 60. AmplifyBio Competitive Strengths & Weaknesses
Table 61. IQVIA Basic Information, Area Served and Competitors
Table 62. IQVIA Major Business
Table 63. IQVIA Preclinical Assets Product and Services
Table 64. IQVIA Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 65. IQVIA Recent Developments/Updates
Table 66. IQVIA Competitive Strengths & Weaknesses
Table 67. ICON plc Basic Information, Area Served and Competitors
Table 68. ICON plc Major Business
Table 69. ICON plc Preclinical Assets Product and Services
Table 70. ICON plc Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 71. ICON plc Recent Developments/Updates
Table 72. ICON plc Competitive Strengths & Weaknesses
Table 73. Medpace Basic Information, Area Served and Competitors
Table 74. Medpace Major Business
Table 75. Medpace Preclinical Assets Product and Services
Table 76. Medpace Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 77. Medpace Recent Developments/Updates
Table 78. Medpace Competitive Strengths & Weaknesses
Table 79. Pharmatest Services Basic Information, Area Served and Competitors
Table 80. Pharmatest Services Major Business
Table 81. Pharmatest Services Preclinical Assets Product and Services
Table 82. Pharmatest Services Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 83. Pharmatest Services Recent Developments/Updates
Table 84. Pharmatest Services Competitive Strengths & Weaknesses
Table 85. PPD Basic Information, Area Served and Competitors
Table 86. PPD Major Business
Table 87. PPD Preclinical Assets Product and Services
Table 88. PPD Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 89. PPD Recent Developments/Updates
Table 90. PPD Competitive Strengths & Weaknesses
Table 91. Crown Bioscience Basic Information, Area Served and Competitors
Table 92. Crown Bioscience Major Business
Table 93. Crown Bioscience Preclinical Assets Product and Services
Table 94. Crown Bioscience Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 95. Crown Bioscience Recent Developments/Updates
Table 96. Crown Bioscience Competitive Strengths & Weaknesses
Table 97. Comparative Biosciences Basic Information, Area Served and Competitors
Table 98. Comparative Biosciences Major Business
Table 99. Comparative Biosciences Preclinical Assets Product and Services
Table 100. Comparative Biosciences Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 101. Comparative Biosciences Recent Developments/Updates
Table 102. Comparative Biosciences Competitive Strengths & Weaknesses
Table 103. TCG Lifesciences Basic Information, Area Served and Competitors
Table 104. TCG Lifesciences Major Business
Table 105. TCG Lifesciences Preclinical Assets Product and Services
Table 106. TCG Lifesciences Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 107. TCG Lifesciences Recent Developments/Updates
Table 108. TCG Lifesciences Competitive Strengths & Weaknesses
Table 109. Domainex Basic Information, Area Served and Competitors
Table 110. Domainex Major Business
Table 111. Domainex Preclinical Assets Product and Services
Table 112. Domainex Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 113. Domainex Recent Developments/Updates
Table 114. Absorption Systems Basic Information, Area Served and Competitors
Table 115. Absorption Systems Major Business
Table 116. Absorption Systems Preclinical Assets Product and Services
Table 117. Absorption Systems Preclinical Assets Revenue, Gross Margin and Market Share (2017-2022) & (USD Million)
Table 118. Preclinical Assets Raw Material
Table 119. Key Manufacturers of Preclinical Assets Raw Materials
Table 120. Preclinical Assets Typical Distributors
Table 121. Preclinical Assets Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Preclinical Assets Picture
Figure 2. World Preclinical Assets Total Market Size: 2017 & 2021 & 2028, (USD Million)
Figure 3. World Preclinical Assets Total Market Size (2017-2028) & (USD Million)
Figure 4. World Preclinical Assets Market Size Market Share by Region (2017-2028)
Figure 5. United States Preclinical Assets Market Size (2017-2028) & (USD Million)
Figure 6. China Preclinical Assets Market Size (2017-2028) & (USD Million)
Figure 7. Europe Preclinical Assets Market Size (2017-2028) & (USD Million)
Figure 8. Japan Preclinical Assets Market Size (2017-2028) & (USD Million)
Figure 9. South Korea Preclinical Assets Market Size (2017-2028) & (USD Million)
Figure 10. ASEAN Preclinical Assets Market Size (2017-2028) & (USD Million)
Figure 11. India Preclinical Assets Market Size (2017-2028) & (USD Million)
Figure 12. Preclinical Assets Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. Producer Shipments of Preclinical Assets by Player Revenue ($MM) and Market Share (%): 2021
Figure 15. Global Four-firm Concentration Ratios (CR4) for Preclinical Assets Markets in 2021
Figure 16. Global Four-firm Concentration Ratios (CR8) for Preclinical Assets Markets in 2021
Figure 17. United States VS China: Preclinical Assets Market Size Market Share Comparison (2017 & 2021 & 2028)
Figure 18. World Preclinical Assets Market Size by Type, (USD Million), 2017 & 2021 & 2028
Figure 19. World Preclinical Assets Market Size Market Share by Type in 2021
Figure 20. Bioanalysis and DMPK Studies
Figure 21. Toxicology Testing
Figure 22. Compound Management
Figure 23. Safety Pharmacology
Figure 24. Others
Figure 25. World Preclinical Assets Market Size Market Share by Type (2017-2028)
Figure 26. World Preclinical Assets Market Size by Application, (USD Million), 2017 & 2021 & 2028
Figure 27. World Preclinical Assets Market Size Market Share by Application in 2021
Figure 28. Biopharmaceutical Companies
Figure 29. Government Institutes
Figure 30. Research institutes
Figure 31. Others
Figure 32. World Preclinical Assets Market Size Market Share by Application (2017-2028)
Figure 33. Manufacturing Cost Structure Analysis of Preclinical Assets in 2021
Figure 34. Manufacturing Process Analysis of Preclinical Assets
Figure 35. Preclinical Assets Industrial Chain
Figure 36. Distribution Channel Breakdown for Preclinical Assets Shipments (%): 2017-2028
Figure 37. Direct Channel Pros & Cons
Figure 38. Indirect Channel Pros & Cons
Figure 39. Methodology
Figure 40. Research Process and Data Source